Cargando…

Molecular Signatures in Skin Associated with Clinical Improvement During Mycophenolate Treatment in Systemic Sclerosis

Heterogeneity in systemic sclerosis/SSc confounds clinical trials. We previously identified ‘intrinsic’ gene expression subsets by analysis of SSc skin. Here we test the hypotheses that skin gene expression signatures including intrinsic subset are associated with skin score/MRSS improvement during...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinchcliff, Monique, Huang, Chiang-Ching, Wood, Tammara A., Mahoney, J. Matthew, Martyanov, Viktor, Bhattacharyya, Swati, Tamaki, Zenshiro, Lee, Jungwha, Carns, Mary, Podlusky, Sofia, Sirajuddin, Arlene, Shah, Sanjiv J, Chang, Rowland W., Lafyatis, Robert, Varga, John, Whitfield, Michael L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714324/ https://www.ncbi.nlm.nih.gov/pubmed/23677167 http://dx.doi.org/10.1038/jid.2013.130

Ejemplares similares

Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures
por: Taroni, Jaclyn N., et al.
Publicado: (2015)

Serum Amyloid A Is a Marker for Pulmonary Involvement in Systemic Sclerosis
por: Lakota, Katja, et al.
Publicado: (2015)

Tenascin-C drives persistence of organ fibrosis
por: Bhattacharyya, Swati, et al.
Publicado: (2016)

Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms
por: Mahoney, J. Matthew, et al.
Publicado: (2015)

Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?
por: Lakota, Katja, et al.
Publicado: (2012)

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis
por: Taroni, Jaclyn N., et al.
Publicado: (2017)

Text data extraction for a prospective, research-focused data mart: implementation and validation
por: Hinchcliff, Monique, et al.
Publicado: (2012)

Identification of cell cycle–regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors
por: Grant, Gavin D., et al.
Publicado: (2013)

A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis
por: Marangoni, Roberta Goncalves, et al.
Publicado: (2015)

Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis
por: Bhattacharyya, Swati, et al.
Publicado: (2018)

Regulator combinations identify systemic sclerosis patients with more severe disease
por: Wang, Yue, et al.
Publicado: (2020)

Measurement of extracellular volume fraction by cardiac magnetic resonance imaging detects diffuse myocardial fibrosis in systemic sclerosis
por: Lee, Daniel C, et al.
Publicado: (2012)

The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy
por: Fang, Feng, et al.
Publicado: (2012)

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature
por: Derrett-Smith, Emma C., et al.
Publicado: (2017)

Fibrosis in systemic sclerosis: common and unique pathobiology
por: Bhattacharyya, Swati, et al.
Publicado: (2012)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
por: Gordon, Jessica K., et al.
Publicado: (2015)

High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis
por: Arron, Sarah T., et al.
Publicado: (2014)

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis
por: Chakravarty, Eliza F., et al.
Publicado: (2015)

Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent Cohorts
por: Johnson, Michael E., et al.
Publicado: (2015)

p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis
por: Ghosh, Asish K, et al.
Publicado: (2013)

Assessment of diffuse myocardial fibrosis in systemic sclerosis by cardiac magnetic resonance imaging
por: Lee, Daniel C, et al.
Publicado: (2013)

Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies
por: Pendergrass, Sarah A., et al.
Publicado: (2012)

High-throughput quantitative histology in systemic sclerosis skin disease using computer vision
por: Correia, Chase, et al.
Publicado: (2020)

Live-cell monitoring of periodic gene expression in synchronous human cells identifies Forkhead genes involved in cell cycle control
por: Grant, Gavin D., et al.
Publicado: (2012)

Mycophenolate-mofetil/mycophenolic-acid: COVID-19: 4 case reports
Publicado: (2021)

Exposure to Mycophenolate and Fatherhood
por: Midtvedt, Karsten, et al.
Publicado: (2017)

Pharmacokinetics of Mycophenolic Acid after Intravenous Administration of Mycophenolate Mofetil to Healthy Cats
por: Slovak, J.E., et al.
Publicado: (2017)

Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis
por: Liao, Yu-Wan, et al.
Publicado: (2022)

Mycophenolic Derivatives from Eupenicilliumparvum
por: Habib, Eman, et al.
Publicado: (2008)

Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
por: Gardiner, Kyle M., et al.
Publicado: (2018)

Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease
por: Jones, Rachel B., et al.
Publicado: (2014)

Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
por: Jia, Yichen, et al.
Publicado: (2018)

Egr-1 Induces a Profibrotic Injury/Repair Gene Program Associated with Systemic Sclerosis
por: Bhattacharyya, Swati, et al.
Publicado: (2011)

Mycophenolate mofetil in the treatment of lupus nephritis
por: Yong, Patrick FK, et al.
Publicado: (2008)

Severe Enteropathy From Mycophenolate Mofetil
por: Jehangir, Asad, et al.
Publicado: (2016)

Mycophenolate versus Cyclophosphamide for Lupus Nephritis
por: Sahay, M., et al.
Publicado: (2018)

Mycophenolate for the Treatment of Primary Sjögren’s Syndrome
por: Chen, Weiqian, et al.
Publicado: (2020)

Autoimmune Gastritis Treated With Mycophenolate Mofetil
por: Harb, Ali H., et al.
Publicado: (2020)

Mycophenolate mofetil: Cytopenia: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5gje70v6dd6ot7diioubfgqiqq